Clear answers. Sources within reach.
Start here, then follow the reference for the experimental details and limitations.
Questions, answered.
Does research-use-only mean a product is suitable for people?
No. Research-use wording is not evidence of suitability for human use. This publication provides no dosing, administration or personal-results guidance.
Does 99% HPLC purity mean a vial contains 99% of its labeled peptide mass?
No. Area purity is a detector-signal fraction under a chromatographic method. Content requires an appropriate quantitative assay with a stated basis.
Does US shipping establish US manufacture?
No. Dispatch location and manufacturing origin are separate facts. Check the exact origin statement and its product scope.
Can a directory authenticate a supplier or its certificate?
No. Our directory attributes public disclosures. It is not an independent factory audit, sample test or certificate-authentication service.
Does a rat tendon-cell study establish BPC-157 efficacy in people?
No. It supports a claim about the specified experimental preparation and endpoints. Human outcomes require a different evidence base and cannot be inferred from migration or receptor-expression measurements alone.
Read the BPC-157 reference & sources →Is one mechanism of BPC-157 fully established?
These papers investigate specific signaling observations and growth-factor responsiveness. They do not establish one universal mechanism that explains every tissue or experimental context.
Read the BPC-157 reference & sources →Is TB-500 always the same as thymosin beta-4?
No single equivalence should be assumed. The cited 2024 study specifies an acetylated seven-residue fragment, while the 1999 wound paper studies thymosin beta-4. Resolve identity from the actual sequence and modification.
Read the TB-500 reference & sources →Can the fragment and its metabolites share one evidence label?
They should be distinguished. The analytical study separated the parent and metabolites and found different assay behavior, illustrating why the tested chemical species matters.
Read the TB-500 reference & sources →Are GHK and GHK-Cu identical research materials?
No. GHK-Cu specifies the copper complex. The selected papers concern that complex, so their findings should not be silently reassigned to the copper-free peptide or another preparation.
Read the GHK-Cu reference & sources →Do the cited studies test a finished skincare product?
No. They investigate experimental wound models and fibroblast biology. A finished product needs its own characterization and relevant evidence.
Read the GHK-Cu reference & sources →Is MOTS-c a peptide or NAD+?
MOTS-c is a mitochondrial-derived peptide. NAD+ is a distinct coenzyme. Both appear in cellular-metabolism discussions, but a shared research context does not make them the same molecule or evidence base.
Read the MOTS-c reference & sources →What does nuclear translocation establish?
The 2018 experiments support a model of stress-associated movement and gene regulation in the studied cells. They do not by themselves establish a clinical or longevity outcome.
Read the MOTS-c reference & sources →Is NAD+ a peptide?
No. It is a coenzyme. Its appearance beside peptide research products is a catalog decision, not a chemical classification.
Read the NAD+ reference & sources →Does cellular NAD+ biology show biofermented NAD+ is better than synthetic NAD+?
No. The cited studies concern cellular measurements and transport, not a comparison of manufacturing routes. Final-material identity, content, impurities and stability need their own evidence.
Read the NAD+ reference & sources →Was the telomerase experiment a human clinical trial?
No. It used cultured human fetal fibroblasts. The origin of the cells does not turn an in-vitro experiment into a clinical study.
Read the Epithalon reference & sources →Do these papers establish longer human lifespan?
No. Their selected endpoints are cultured-cell telomerase/telomere measurements and hormonal observations in rhesus monkeys, not human lifespan outcomes.
Read the Epithalon reference & sources →What has Semax research measured?
The selected papers measured molecular responses in rat ischemia models, including gene expression and selected proteins. They answer narrower questions than a broad claim about cognition.
Read the Semax reference & sources →Does a pathway change prove a practical benefit?
No. A measured pathway response needs model-specific interpretation and does not by itself establish a functional or clinical outcome.
Read the Semax reference & sources →Is Selank’s mechanism fully established?
The selected studies support hypotheses about GABA-related signaling, while showing that responses depend on the experimental context. They do not establish one complete mechanism.
Read the Selank reference & sources →Did Selank change every tested GABA-related gene?
No. In the IMR-32 experiment, Selank alone did not alter the measured transcript panel, although combination conditions behaved differently.
Read the Selank reference & sources →What is ipamorelin in research?
It is a synthetic pentapeptide investigated as a growth-hormone secretagogue, with early laboratory/animal pharmacology and human concentration-response work.
Read the Ipamorelin reference & sources →Is a hormonal endpoint the same as a functional outcome?
No. Measuring growth hormone establishes the observed response in the study; it does not by itself establish a separate physiological or practical outcome.
Read the Ipamorelin reference & sources →Does CJC-1295 research automatically apply to no-DAC products?
No. The cited studies concern a defined albumin-binding analogue. Removing that feature changes the identity and invalidates automatic transfer of its time-course findings.
Read the CJC-1295 reference & sources →What does preserved pulsatility mean here?
It describes the hormone pattern observed in a particular sampling experiment, not a universal statement about safety or functional outcomes.
Read the CJC-1295 reference & sources →Why does the study population matter?
The selected trials enrolled participants in a specific HIV-associated adiposity context. Extending the findings to another population requires applicable evidence rather than a shared endpoint name.
Read the Tesamorelin reference & sources →Does an imaging change establish every clinical outcome?
No. The 2014 paper distinguishes measured fat changes from questions about clinical importance and longer-term consequences.
Read the Tesamorelin reference & sources →What does KPV stand for?
It denotes the amino-acid sequence lysine–proline–valine. A full laboratory specification still needs structural and analytical detail.
Read the KPV reference & sources →Why do KPV delivery studies need separate interpretation?
Nanoparticles, hydrogel composition and targeting modifications are part of the tested preparation. Their results cannot automatically be assigned to unformulated KPV.
Read the KPV reference & sources →